title: Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
abstract: We have carried out a phase II study in advanced or metastatic transitional cell carcinoma of the bladder. Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy. Treatment consisted of ifosfamide 1000 mg/sm in a 2-hour infusion for 5 consecutive days from d.1 to d.5. Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion. Twenty patients entered the study and received a total of 62 cycles: the treatment resulted feasible on an outpatient basis, with mild toxicity. Only one partial response was observed. With this dose and schedule, ifosfamide appeared less effective than in a previous report at higher doses. Toxicity was acceptable.
authors.affiliation: U.O. Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: A
authors.initials: A
authors.lastname: Vigani
authors.forename: F
authors.initials: F
authors.lastname: Pensa
authors.forename: M
authors.initials: M
authors.lastname: Vanoli
authors.forename: F
authors.initials: F
authors.lastname: Tani
authors.forename: F
authors.initials: F
authors.lastname: Vaira
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000553:Ambulatory Care; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D002423:Cause of Death; D018450:Disease Progression; D004334:Drug Administration Schedule; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008297:Male; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D018906:Antineoplastic Agents, Alkylating; D005100:Expectorants; D015080:Mesna; D007069:Ifosfamide